ARCH Venture Partners Founded 1986
Founders Clinton Bybee Keith Crandell Robert Nelsen Steven Lazarus
Overview
Portfolio analytics
Team
Investments
News & Media
Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 378
Average round size
info
The average size of a deal this fund participated in
$45M
Portfolio companies 155
Rounds per year 4.43
Lead investments 43
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.51
Exits 63
Stages of investment
Early Stage Venture
Seed
Areas of investment
Biotechnology
Electronics
Health Care
Industrial
Software
Summary

In 1986 was created ARCH Venture Partners, which is appeared as VC. The leading representative office of defined VC is situated in the Chicago. The venture was found in North America in United States.

The fund was created by Clinton W. Bybee, Keith L. Crandell, Robert Nelsen, Steven Lazarus. We also calculated 6 valuable employees in our database.

The typical case for the fund is to invest in rounds with 5-6 participants. Despite the ARCH Venture Partners, startups are often financed by Lux Capital, In-Q-Tel, Alexandria Real Estate Equities. The meaningful sponsors for the fund in investment in the same round are Wellcome Trust, Third Rock Ventures, Sofinnova Investments. In the next rounds fund is usually obtained by Wellcome Trust, Versant Ventures, Lux Capital.

The fund has no specific favorite in a number of founders of portfolio startups. If startup sums 4 of the founder, the chance for it to be financed is low. We can highlight the next thriving fund investment areas, such as Software, Medical. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Among the various public portfolio startups of the fund, we may underline Juno Therapeutics, Receptos, GRAIL Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund.

The fund is constantly included in 7-12 investment rounds annually. The higher amount of exits for fund were in 2015. When the investment is from ARCH Venture Partners the average startup value is 50-100 millions dollars. This ARCH Venture Partners works on 7 percentage points less the average amount of lead investments comparing to the other organizations. The high activity for fund was in 2018. Despite it in 2019 the fund had an activity. The common things for fund are deals in the range of 10 - 50 millions dollars. The real fund results show that this VC is 0 percentage points less often commits exit comparing to other companies.

Read more
Notable deals
CompanyIndustryRoundRound SizeDateInvestorsLocation
HiberCell
Biotechnology
Health Care
Health Diagnostics
Medical
Early Stage Venture
67M19 May 2021 United States, New York
Early Stage Venture
105M28 Apr 2021
Ultivue
Biopharma
Biotechnology
Pharmaceutical
Late Stage Venture
50M27 Apr 2021 United States, Cambridge
Vizgen
Biotechnology
Early Stage Venture
37M07 Apr 2021 United States, Cambridge
Seed
32M06 Apr 2021
Late Stage Venture
40M31 Mar 2021
Insitro
Biotechnology
Life Science
Machine Learning
Pharmaceutical
Late Stage Venture
400M15 Mar 2021 United States, South San Francisco
EGenesis
Biopharma
Biotechnology
Genetics
Life Science
Medical
Late Stage Venture
125M02 Mar 2021 United States, Cambridge
Vividion Therapeutics
Biotechnology
Health Care
Therapeutics
Late Stage Venture
135M24 Feb 2021 United States, San Diego
News
Slingshot Biosciences Announces $23 Million in Series A Financing
– Slingshot Biosciences closed a $23m Series A financing. – The investment was led by Northpond Ventures, with participation from ARCH Venture Partners and Anterra Capital. – The new funding will enable Slingshot to accelerate the commercialization of its synthetic cell products spanning controls, diagnostics, and adoptive cell therapies. – Adam Wieschhaus, PhD, Director at Northpond Ventures, and Corey Ritter, Senior Associate at ARCH Venture Partners, will join the Board of Directors. – Slingshot w... Read more
Prime Medicine Raises $315M in Funding
– Prime Medicine is a Cambridge MA-based biotechnology company developing gene editing technology. – The company raised $115M in Series A funding and $200M in Series B funding. – The Series A round was led by ARCH Venture Partners with participation from F-Prime Capital, GV, and Newpath Partners. – The Series B included all Series A investors, plus Casdin Capital with participation from Cormorant Asset Management, Moore Strategic Ventures, Public Sector Pension Investment Board, Redmile Group and Samsara B... Read more
Review
  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent ARCH Venture Partners?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Crunchbase icon

Content report

The following text will be sent to our editors: